Now showing items 419-438 of 1063

    • Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 

      Smyth, EC; Verheij, M; Allum, W; Cunningham, D; Cervantes, A; Arnold, D; ESMO Guidelines Committee (2016-09)
    • Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. 

      Seed, G; Yuan, W; Mateo, J; Carreira, S; Bertan, C; Lambros, M; Boysen, G; Ferraldeschi, R; Miranda, S; Figueiredo, I; Riisnaes, R; Crespo, M; Rodrigues, DN; Talevich, E; Robinson, DR; Kunju, LP; Wu, Y-M; Lonigro, R; Sandhu, S; Chinnaiyan, AM; de Bono, JS (2017-10)
      <b>Purpose:</b> Precise detection of copy number aberrations (CNA) from tumor biopsies is critically important to the treatment of metastatic prostate cancer. The use of targeted panel next-generation sequencing (NGS) is ...
    • Gene expression profiling identifies distinct molecular subgroups of leiomyosarcoma with clinical relevance. 

      Lee, Y-F; Roe, T; Mangham, DC; Fisher, C; Grimer, RJ; Judson, I (2016-10)
      Background Soft tissue sarcomas are heterogeneous and a major complication in their management is that the existing classification scheme is not definitive and is still evolving. Leiomyosarcomas, a major histologic category ...
    • Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. 

      Wongchenko, MJ; McArthur, GA; Dréno, B; Larkin, J; Ascierto, PA; Sosman, J; Andries, L; Kockx, M; Hurst, SD; Caro, I; Rooney, I; Hegde, PS; Molinero, L; Yue, H; Chang, I; Amler, L; Yan, Y; Ribas, A (2017-09)
      Purpose: The association of tumor gene expression profiles with progression-free survival (PFS) outcomes in patients with BRAFV600-mutated melanoma treated with vemurafenib or cobimetinib combined with vemurafenib was ...
    • Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer. 

      Hermanova, I; Zúñiga-García, P; Caro-Maldonado, A; Fernandez-Ruiz, S; Salvador, F; Martín-Martín, N; Zabala-Letona, A; Nuñez-Olle, M; Torrano, V; Camacho, L; Lizcano, JM; Talamillo, A; Carreira, S; Gurel, B; Cortazar, AR; Guiu, M; López, JI; Martinez-Romero, A; Astobiza, I; Valcarcel-Jimenez, L; Lorente, M; Arruabarrena-Aristorena, A; Velasco, G; Gomez-Muñoz, A; Suárez-Cabrera, C; Lodewijk, I; Flores, JM; Sutherland, JD; Barrio, R; de Bono, JS; Paramio, JM; Trka, J; Graupera, M; Gomis, RR; Carracedo, A (2020-06)
      Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form ...
    • Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. 

      Machiela, MJ; Hofmann, JN; Carreras-Torres, R; Brown, KM; Johansson, M; Wang, Z; Foll, M; Li, P; Rothman, N; Savage, SA; Gaborieau, V; McKay, JD; Ye, Y; Henrion, M; Bruinsma, F; Jordan, S; Severi, G; Hveem, K; Vatten, LJ; Fletcher, T; Koppova, K; Larsson, SC; Wolk, A; Banks, RE; Selby, PJ; Easton, DF; Pharoah, P; Andreotti, G; Freeman, LEB; Koutros, S; Albanes, D; Mannisto, S; Weinstein, S; Clark, PE; Edwards, TE; Lipworth, L; Gapstur, SM; Stevens, VL; Carol, H; Freedman, ML; Pomerantz, MM; Cho, E; Kraft, P; Preston, MA; Wilson, KM; Gaziano, JM; Sesso, HS; Black, A; Freedman, ND; Huang, W-Y; Anema, JG; Kahnoski, RJ; Lane, BR; Noyes, SL; Petillo, D; Colli, LM; Sampson, JN; Besse, C; Blanche, H; Boland, A; Burdette, L; Prokhortchouk, E; Skryabin, KG; Yeager, M; Mijuskovic, M; Ognjanovic, M; Foretova, L; Holcatova, I; Janout, V; Mates, D; Mukeriya, A; Rascu, S; Zaridze, D; Bencko, V; Cybulski, C; Fabianova, E; Jinga, V; Lissowska, J; Lubinski, J; Navratilova, M; Rudnai, P; Szeszenia-Dabrowska, N; Benhamou, S; Cancel-Tassin, G; Cussenot, O; Bueno-de-Mesquita, HB; Canzian, F; Duell, EJ; Ljungberg, B; Sitaram, RT; Peters, U; White, E; Anderson, GL; Johnson, L; Luo, J; Buring, J; Lee, I-M; Chow, W-H; Moore, LE; Wood, C; Eisen, T; Larkin, J; Choueiri, TK; Lathrop, GM; Teh, BT; Deleuze, J-F; Wu, X; Houlston, RS; Brennan, P; Chanock, SJ; Scelo, G; Purdue, MP (2017-11)
      Background Relative telomere length in peripheral blood leukocytes has been evaluated as a potential biomarker for renal cell carcinoma (RCC) risk in several studies, with conflicting findings.Objective We performed an ...
    • Genome-wide association study identifies multiple risk loci for renal cell carcinoma. 

      Scelo, G; Purdue, MP; Brown, KM; Johansson, M; Wang, Z; Eckel-Passow, JE; Ye, Y; Hofmann, JN; Choi, J; Foll, M; Gaborieau, V; Machiela, MJ; Colli, LM; Li, P; Sampson, JN; Abedi-Ardekani, B; Besse, C; Blanche, H; Boland, A; Burdette, L; Chabrier, A; Durand, G; Le Calvez-Kelm, F; Prokhortchouk, E; Robinot, N; Skryabin, KG; Wozniak, MB; Yeager, M; Basta-Jovanovic, G; Dzamic, Z; Foretova, L; Holcatova, I; Janout, V; Mates, D; Mukeriya, A; Rascu, S; Zaridze, D; Bencko, V; Cybulski, C; Fabianova, E; Jinga, V; Lissowska, J; Lubinski, J; Navratilova, M; Rudnai, P; Szeszenia-Dabrowska, N; Benhamou, S; Cancel-Tassin, G; Cussenot, O; Baglietto, L; Boeing, H; Khaw, K-T; Weiderpass, E; Ljungberg, B; Sitaram, RT; Bruinsma, F; Jordan, SJ; Severi, G; Winship, I; Hveem, K; Vatten, LJ; Fletcher, T; Koppova, K; Larsson, SC; Wolk, A; Banks, RE; Selby, PJ; Easton, DF; Pharoah, P; Andreotti, G; Freeman, LEB; Koutros, S; Albanes, D; Männistö, S; Weinstein, S; Clark, PE; Edwards, TL; Lipworth, L; Gapstur, SM; Stevens, VL; Carol, H; Freedman, ML; Pomerantz, MM; Cho, E; Kraft, P; Preston, MA; Wilson, KM; Michael Gaziano, J; Sesso, HD; Black, A; Freedman, ND; Huang, W-Y; Anema, JG; Kahnoski, RJ; Lane, BR; Noyes, SL; Petillo, D; Teh, BT; Peters, U; White, E; Anderson, GL; Johnson, L; Luo, J; Buring, J; Lee, I-M; Chow, W-H; Moore, LE; Wood, C; Eisen, T; Henrion, M; Larkin, J; Barman, P; Leibovich, BC; Choueiri, TK; Mark Lathrop, G; Rothman, N; Deleuze, J-F; McKay, JD; Parker, AS; Wu, X; Houlston, RS; Brennan, P; Chanock, SJ (2017-06-09)
      Previous genome-wide association studies (GWAS) have identified six risk loci for renal cell carcinoma (RCC). We conducted a meta-analysis of two new scans of 5,198 cases and 7,331 controls together with four existing ...
    • Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. 

      Zafeiriou, Z; Bianchini, D; Chandler, R; Rescigno, P; Yuan, W; Carreira, S; Barrero, M; Petremolo, A; Miranda, S; Riisnaes, R; Rodrigues, DN; Gurel, B; Sumanasuriya, S; Paschalis, A; Sharp, A; Mateo, J; Tunariu, N; Chinnaiyan, AM; Pritchard, CC; Kelly, K; de Bono, JS (2019-01)
      Platinum-based regimens have not been proved to increase survival from advanced prostate cancer (PCa). Incontrovertible evidence that a proportion of prostate cancers have homologous recombination DNA (HRD) repair defects, ...
    • Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative. 

      Aftimos, P; Oliveira, M; Irrthum, A; Fumagalli, D; Sotiriou, C; Nili Gal-Yam, E; Robson, ME; Ndozeng, J; Di Leo, A; Ciruelos, EM; de Azambuja, E; Viale, G; Scheepers, ED; Curigliano, G; Bliss, JM; Reis-Filho, JS; Colleoni, M; Balic, M; Cardoso, F; Albanell, J; Duhem, C; Marreaud, S; Romagnoli, D; Rojas, B; Gombos, A; Wildiers, H; Guerrero-Zotano, A; Hall, P; Bonetti, A; Larsson, KF; Degiorgis, M; Khodaverdi, S; Greil, R; Sverrisdottir, A; Paoli, M; Seyll, E; Loibl, S; Linderholm, B; Zoppoli, G; Davidson, NE; Johannsson, OT; Bedard, PL; Loi, S; Knox, S; Cameron, DA; Harbeck, N; Lasa Montoya, M; Brandão, M; Vingiani, A; Caballero, C; Hilbers, FS; Yates, LR; Benelli, M; Venet, D; Piccart, MJ (2021-06-28)
      AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor and metastasis ...
    • Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. 

      Woolston, A; Khan, K; Spain, G; Barber, LJ; Griffiths, B; Gonzalez-Exposito, R; Hornsteiner, L; Punta, M; Patil, Y; Newey, A; Mansukhani, S; Davies, MN; Furness, A; Sclafani, F; Peckitt, C; Jiménez, M; Kouvelakis, K; Ranftl, R; Begum, R; Rana, I; Thomas, J; Bryant, A; Quezada, S; Wotherspoon, A; Khan, N; Fotiadis, N; Marafioti, T; Powles, T; Lise, S; Calvo, F; Guettler, S; von Loga, K; Rao, S; Watkins, D; Starling, N; Chau, I; Sadanandam, A; Cunningham, D; Gerlinger, M (2019-07)
      Despite biomarker stratification, the anti-EGFR antibody cetuximab is only effective against a subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis of the cetuximab resistance landscape in 35 RAS ...
    • Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. 

      Shern, JF; Selfe, J; Izquierdo, E; Patidar, R; Chou, H-C; Song, YK; Yohe, ME; Sindiri, S; Wei, J; Wen, X; Rudzinski, ER; Barkauskas, DA; Lo, T; Hall, D; Linardic, CM; Hughes, D; Jamal, S; Jenney, M; Chisholm, J; Brown, R; Jones, K; Hicks, B; Angelini, P; George, S; Chesler, L; Hubank, M; Kelsey, A; Gatz, SA; Skapek, SX; Hawkins, DS; Shipley, JM; Khan, J
      Purpose Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent disease remains poor, and beyond <i>PAX-FOXO1</i> ...
    • Genomic correlates of clinical outcome in advanced prostate cancer. 

      Abida, W; Cyrta, J; Heller, G; Prandi, D; Armenia, J; Coleman, I; Cieslik, M; Benelli, M; Robinson, D; Van Allen, EM; Sboner, A; Fedrizzi, T; Mosquera, JM; Robinson, BD; De Sarkar, N; Kunju, LP; Tomlins, S; Wu, YM; Nava Rodrigues, D; Loda, M; Gopalan, A; Reuter, VE; Pritchard, CC; Mateo, J; Bianchini, D; Miranda, S; Carreira, S; Rescigno, P; Filipenko, J; Vinson, J; Montgomery, RB; Beltran, H; Heath, EI; Scher, HI; Kantoff, PW; Taplin, M-E; Schultz, N; deBono, JS; Demichelis, F; Nelson, PS; Rubin, MA; Chinnaiyan, AM; Sawyers, CL (2019-06)
      Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of this heterogeneity on clinical outcome. Here, ...
    • Genomic Instability and <i>TP53</i> Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment. 

      Schuster, EF; Gellert, P; Segal, CV; López-Knowles, E; Buus, R; Cheang, MCU; Morden, J; Robertson, J; Bliss, JM; Smith, I; Dowsett, M; POETIC Trial Management Group and Trialists (2019-01)
      Purpose Although aromatase inhibitor (AI) treatment is effective in estrogen receptor-positive postmenopausal breast cancer, resistance is common and incompletely explained. Genomic instability, as measured by somatic copy ...
    • Genomic loss of heterozygosity and survival in the REAL3 trial. 

      Smyth, EC; Cafferkey, C; Loehr, A; Waddell, T; Begum, R; Peckitt, C; Harding, TC; Nguyen, M; Okines, AF; Raponi, M; Rao, S; Watkins, D; Starling, N; Middleton, GW; Wadsley, J; Mansoor, W; Crosby, T; Wotherspoon, A; Chau, I; Cunningham, D (2018-11-30)
      Background Homologous recombination deficiency (HRD) measured using a genomic signature for loss of heterozygosity (LOH) predicts benefit from rucaparib in ovarian cancer. We hypothesized that some oesophagogastric cancers ...
    • Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC). 

      Barry, GS; Cheang, MC; Chang, HL; Kennecke, HF (2016-04)
      A prospective study was conducted to identify biomarkers associated with resistance to panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). Patients with previously treated, codon 12/13 KRAS wt, ...
    • Genomic profile of advanced breast cancer in circulating tumour DNA. 

      Kingston, B; Cutts, RJ; Bye, H; Beaney, M; Walsh-Crestani, G; Hrebien, S; Swift, C; Kilburn, LS; Kernaghan, S; Moretti, L; Wilkinson, K; Wardley, AM; Macpherson, IR; Baird, RD; Roylance, R; Reis-Filho, JS; Hubank, M; Faull, I; Banks, KC; Lanman, RB; Garcia-Murillas, I; Bliss, JM; Ring, A; Turner, NC (2021-04-23)
      The genomics of advanced breast cancer (ABC) has been described through tumour tissue biopsy sequencing, although these approaches are limited by geographical and temporal heterogeneity. Here we use plasma circulating ...
    • Genomics of lethal prostate cancer at diagnosis and castration resistance. 

      Mateo, J; Seed, G; Bertan, C; Rescigno, P; Dolling, D; Figueiredo, I; Miranda, S; Nava Rodrigues, D; Gurel, B; Clarke, M; Atkin, M; Chandler, R; Messina, C; Sumanasuriya, S; Bianchini, D; Barrero, M; Petermolo, A; Zafeiriou, Z; Fontes, M; Perez-Lopez, R; Tunariu, N; Fulton, B; Jones, R; McGovern, U; Ralph, C; Varughese, M; Parikh, O; Jain, S; Elliott, T; Sandhu, S; Porta, N; Hall, E; Yuan, W; Carreira, S; de Bono, JS (2020-04)
      The genomics of primary prostate cancer differ from those of metastatic castration-resistant prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer biopsies from patients who developed mCRPC, ...
    • Germline mutations in the PAF1 complex gene CTR9 predispose to Wilms tumour. 

      Hanks, S; Perdeaux, ER; Seal, S; Ruark, E; Mahamdallie, SS; Murray, A; Ramsay, E; Del Vecchio Duarte, S; Zachariou, A; de Souza, B; Warren-Perry, M; Elliott, A; Davidson, A; Price, H; Stiller, C; Pritchard-Jones, K; Rahman, N (2014-08-07)
      Wilms tumour is a childhood kidney cancer. Here we identify inactivating CTR9 mutations in 3 of 35 Wilms tumour families, through exome and Sanger sequencing. By contrast, no similar mutations are present in 1,000 population ...
    • Glycogen synthase kinase 3 controls migration of the neural crest lineage in mouse and Xenopus. 

      Gonzalez Malagon, SG; Lopez Muñoz, AM; Doro, D; Bolger, TG; Poon, E; Tucker, ER; Adel Al-Lami, H; Krause, M; Phiel, CJ; Chesler, L; Liu, KJ (2018-03-19)
      Neural crest migration is critical to its physiological function. Mechanisms controlling mammalian neural crest migration are comparatively unknown, due to difficulties accessing this cell population in vivo. Here we report ...
    • Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. 

      Newsome, PN; Fox, R; King, AL; Barton, D; Than, N-N; Moore, J; Corbett, C; Townsend, S; Thomas, J; Guo, K; Hull, D; Beard, HA; Thompson, J; Atkinson, A; Bienek, C; McGowan, N; Guha, N; Campbell, J; Hollyman, D; Stocken, D; Yap, C; Forbes, SJ (2018-01)
      Background Results of small-scale studies have suggested that stem-cell therapy is safe and effective in patients with liver cirrhosis, but no adequately powered randomised controlled trials have been done. We assessed the ...